patients, mostly by surgical interventions (n=6). 35 patients had previously had a failed diagnostic bronchoscopy. Of these patients, the addition of ENB allowed a diagnosis in 14 cases. 8 underwent an ENB directly upon assessment of the clinical data. The anatomical positioning of the lesion was without consequence for the diagnostic yield. The diagnostic yield increased significantly with the size of the lesion (<2 cm: 15%, 2–3 cm: 57%, >3 cm: 50%, p<0.001).

Conclusions: ENB is a useful diagnostic method in the hands of a skilled interventional respiratory physician, particularly where conventional bronchoscopy has failed. Although the anatomical location does not affect the accuracy of the results, lesions over 2 cm in size are more likely to be amenable to this procedure. The overall diagnostic yield lies lower than those quoted in previous studies, so that selective use of this procedure should be considered.

Abstract P181 Table 1

<table>
<thead>
<tr>
<th>p Value</th>
<th>OR</th>
<th>95% CI for OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Area = lung</td>
<td>0.472</td>
<td>1.391</td>
</tr>
<tr>
<td>Lesion distance from pleura ≤2</td>
<td>0.001</td>
<td>3.862</td>
</tr>
<tr>
<td>Lesion size ≤2</td>
<td>0.014</td>
<td>3.653</td>
</tr>
<tr>
<td>More than 2 passes</td>
<td>0.755</td>
<td>0.848</td>
</tr>
<tr>
<td>Needle pleural angle ≤45</td>
<td>0.368</td>
<td>1.420</td>
</tr>
</tbody>
</table>

Z Sheikh, E Woo, T Meagher. Buckinghamshire Hospital NHS Trust, Aylesbury, UK

Introduction and Objectives: CT guided lung biopsy is a proven diagnostic method for lung cancer. However, traditionally complication rates from this procedure have been high. The aim of our study was to assess current complication rates from this procedure and the determine what possible risk factors may account for these.

Methods: A retrospective cohort of CT guided lung biopsy procedures done between August 2008 and November 2010 were analysed. Patient notes and electronic radiology records (Centricity PACS) were reviewed. Complications of haemorrhage, pneumothorax, and death were recorded and the sample adequacy of biopsy specimens for pathological examination was determined for each procedure. A univariate analysis was performed for determining the risk of post-biopsy pneumothorax and biopsy type (core or FNA), number of co-axial needle passes, needle pleural angle, lesion size, and lesion distance from pleura at point of biopsy, and lesion location (lung or mediastinal). Consequently, a multiple logistic regression analysis was performed on the most significantly correlated risk factors for pneumothorax from the univariate analysis.

Results: Exactly 200 biopsy procedures done in 184 patients were included of which 64% were core biopsies (n=128). The mean age was 69 years (range 31–90 years) with 79.9% of patients over 65 years old (n=151) and 59.8% of patients male (n=119). Haemorrhage occurred in 2.5% (n=5) and pneumothorax in 17% (n=34) with 5% (n=10) of procedures requiring intercostals chest drain insertion for pneumothorax. No deaths were recorded. A statistically significant higher risk was observed for core biopsy (OR 3.65, p=0.001, 95% CI 1.38 to 9.65) and lesion distance from pleura >2 cm (OR 4.13, p=0.001, 95% CI 1.88 to 9.08). A multivariate analysis showed that the risk was greatest when core biopsies were taken from lesions more than 2 cm from the pleura at point of biopsy (OR 9.14, p=0.001, 95% CI 2.72 to 30.69). The sample adequacy rate was 95.5% (n=191).

Conclusions: In this recent study all complication rates were found to be lower than that reported in the national survey which is the current standard for BTS guidelines on acceptable complication rates. However, a higher rate of intercostal drain insertion was observed. Lesion distance from pleura at point of biopsy >2 cm and core biopsies were the most significant risk factors for post-biopsy pneumothorax and operators should consider these prior to biopsy. Larger studies are needed to reases current national complication rates and target complication rates may need to be specified by biopsy type.

Abstract P181 Table 2

<table>
<thead>
<tr>
<th>p Value</th>
<th>OR</th>
<th>95% CI for OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion distance from pleura ≤2</td>
<td>&lt;0.001</td>
<td>4.129</td>
</tr>
<tr>
<td>Biopsy type = core</td>
<td>0.009</td>
<td>3.647</td>
</tr>
</tbody>
</table>

Abstract P181 Table 3

<table>
<thead>
<tr>
<th>p Value</th>
<th>OR</th>
<th>95% CI for OR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lesion distance from pleura &amp; biopsy type</td>
<td>&lt;0.001</td>
<td>Reference category</td>
</tr>
<tr>
<td>Lesion distance &lt;2 &amp; type=FNA</td>
<td>0.524</td>
<td>1.478</td>
</tr>
<tr>
<td>Lesion distance &lt;2 &amp; type=core</td>
<td>0.941</td>
<td>0.935</td>
</tr>
<tr>
<td>Lesion distance ≥2 &amp; type=core</td>
<td>&lt;0.001</td>
<td>9.137</td>
</tr>
</tbody>
</table>

S M Kazmi, S Sureshkumar, A Nazir, D Nazareth, J Greenwood, M Ledson, M Walshaw. Liverpool Heart and Chest Hospital, Liverpool, UK

Introduction: PET scans are useful in lung cancer by facilitating accurate staging to ensure that optimal treatment can be offered. Although the European Association of Nuclear Medicine (EANM) has produced reporting guidelines, the utility of the test depends upon the interpretation of the obtained images by the reporting radiologist. Since most UK PET services are provided by the independent sector (IS) remote from cancer units, we were interested to assess the value of PET/CT reporting in the MDT management of lung cancer.

Methods: We looked at the quality of reports of all 97 PET/CT scans performed in our busy lung cancer unit between December 2010 and April 2011, measuring the reports (from 6 IS radiologists) against the EANM standards. In addition, we analysed the length of the report and documentation of PET staging.

Results: FDG accumulation was documented in standard guideline format (mild, moderate or intense) in 39 cases (40%), all with SUVs noted, but in 37 cases (38%) FDG accumulation was described as significant, increased or highgrade (36 with SUVs). However, 21 scans (22%) had no report of FDG accumulation but 20 (90%) still described SUVs. Corresponding CT findings were recorded in 93 (96%), and a summary report was issued in 94 (97%), but 33 reports (34%) were >1 page in length. Seven scans showed benign disease and 8 had no excess FDG activity: of the remaining 82 with malignancy, only 39 (48%) were staged. Reasons for not staging included “inflammatory changes” (2), “uncertain findings” (18),

doi:10.1136/thoraxjnl-2011-201054c.182

doi:10.1136/thoraxjnl-2011-201054c.181

doi:10.1136/thoraxjnl-2011-201054c.182

doi:10.1136/thoraxjnl-2011-201054c.182
P181 Complications from CT guided lung biopsies and risk factors for pneumothorax

Z Sheikh, E Woo and T Meagher

Thorax 2011 66: A141
doi: 10.1136/thoraxjnl-2011-201054c.181

Updated information and services can be found at:
http://thorax.bmj.com/content/66/Suppl_4/A141.1

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Screening (oncology) (407)
- Lung cancer (oncology) (670)
- Lung cancer (respiratory medicine) (670)
- Lung neoplasms (608)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/